Prevalence, costs, and treatment of Alzheimer's disease and related dementia: A managed care perspective

American Journal of Managed Care

Volumn 7, Issue 8, 2001, Pages 809-818

  Rice, D P ^a   Fillit, H M ^a   Max, W ^a   Knopman, D S ^a   Lloyd, J R ^a   Duttagupta, S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; PLACEBO; RIVASTIGMINE; TACRINE;

AGE; ALZHEIMER DISEASE; ARTICLE; CAREGIVER; CLINICAL PROTOCOL; CLINICAL TRIAL; COGNITION; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DEMENTIA; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG TOLERABILITY; DRUG USE; EARLY DIAGNOSIS; EVIDENCE BASED MEDICINE; GERIATRIC PATIENT; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH INSURANCE; HUMAN; LONG TERM CARE; MANAGED CARE; MANAGED CARE ORGANIZATION; MEDICAID; MEDICAL INFORMATION; MEDICAL LITERATURE; MEDICARE; MORBIDITY; PATIENT CARE; PREVALENCE; PRIORITY JOURNAL; PRODUCTIVITY; SALARY; SIDE EFFECT; SUPPORT GROUP;

AGED; ALZHEIMER DISEASE; COGNITION DISORDERS; COST OF ILLNESS; FEMALE; HUMANS; INDANS; MALE; MANAGED CARE PROGRAMS; MEDICAID; NOOTROPIC AGENTS; PIPERIDINES; PREVALENCE; UNITED STATES;

EID: 0034861814     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Economic considerations in Alzheimer's disease
2. Epidemiology of dementia and Alzheimer's disease
3. Alzheimer's disease management
4. How much do persons with Alzheimer's disease cost Medicare?
5. Treatment of Alzheimer's disease patients in a managed care organization: A descriptive study of costs and utilization
6. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset
7. Estimated prevalence of Alzheimer's disease in the United States
8. The economic cost of Alzheimer's disease and related dementias to the California Medicaid program ("Medi-Cal") in 1995
9. Alzheimer's disease under managed care: Implications from Medicare utilization and expenditure patterns
10. Very old women at highest risk of dementia and Alzheimer's disease: Incidence data from the Kungsholmen Project, Stockholm
11. Misclassification and selection bias when identifying Alzheimer's disease solely from Medicare claims records
12. Cost of Alzheimer's disease and related dementia in managed Medicare
13. The cost of institutional care in Alzheimer's disease: Nursing home and hospital use in a prospective cohort
14. Use of large databases for outcomes research
15. Using healthcare claims data for outcomes research and pharmacoeconomic analyses
16. Alzheimer's disease care: Costs and potential savings
17. The economic impact of Alzheimer's disease
18. Prevalence and impact of medical comorbidity in Alzheimer's disease
19. Pharmacoeconomics: Determining the value of functional independence and quality of life in Alzheimer's disease
20. The economic burden of Alzheimer's disease care
21. The economic value of informal caregiving
22. Alzheimer's disease: The unpaid burden of caring
23. The cost of Alzheimer's disease in managed care: A cross-sectional study
24. The US economic and social costs of Alzheimer's disease revisited
25. Psychiatric and physical morbidity effects of dementia caregiving: Prevalence, correlates, and causes
26. The health impact of living with a cognitively impaired elderly spouse
27. Spousal caregivers of dementia victims: Longitudinal changes in immunity and health
28. Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada
29. Mental health services for Alzheimer's disease: Current trends in reimbursement and public policy and the future under managed care
30. The net cost of Alzheimer disease and related dementia: A population-based study of Georgia Medicaid recipients
31. The economic cost of Alzheimer's disease to a state Medicaid program
32. Unmet needs in the management of Alzheimer's disease: A managed care perspective
33. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial
34. Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis
35. E2020: The pharmacology of a piperidine cholinesterase inhibitor
36. Recent developments in the drug treatment of Alzheimer's disease
37. Potential savings in the cost of caring for Alzheimer's disease: Treatment with rivastigmine
38. Potential savings in the cost of caring for Alzheimer's disease: Treatment with rivastigmine
39. Guidelines for the appropriate use of cholinesterase inhibitors in patients with Alzheimer's disease
40. Donepezil enhances global function, cognition, and activities of daily living compared to placebo in a 1-year, double-blind trial in patients with mild to moderate Alzheimer's disease
41. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: An interim analysis of the results of a US multicentre open label extension study
42. An evaluation of the long-term efficacy of donepezil in patients from a phase III clinical extension trial
43. An economic evaluation of donepezil in the treatment of Alzheimer's disease
44. Donepezil use in managed Medicare: Effect on health care costs and utilization
45. The impact of donepezil on caregiving burden for patients with Alzheimer's disease
46. Donepezil use and impact on cost among patients with Alzheimer's disease in the Veteran's Health Administration
47. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease